Russ Conroy

Investigators also report that disease-free survival was not associated with regional node irradiation treatment in favorable-risk, node-positive breast cancer.

Data from a phase 2 trial support a supplemental new drug application for isavuconazonium sulfate as a treatment for pediatric patients with invasive aspergillosis or invasive mucormycosis.

Findings from the CROSS-FIRE study may inform individualized decision-making regarding stereotactic radiosurgery for patients with small cell lung cancer, according to Chad Rusthoven, MD.

Implementation of a personalized, proactive care pathway for breast cancer survivors will be evaluated in future clinical trials, according to one of the authors of a pilot implementation study.

The FDA requires data from an additional clinical trial to support the potential approval of avasopasem for managing radiation-induced severe oral mucositis in patients with head and neck cancer.

The therascreen PDGFRA RGQ PCR kit has become the first FDA-approved companion diagnostic designed to detect platelet-derived growth factor receptor alpha gene mutations.

Michael Ganio, PharmD, MS, BCPS, FASHP, addresses some challenges concerning the ongoing chemotherapy shortage in the United States, and how communication among clinical teams may mitigate it.

Investigators plan to launch a controlled trial assessing remestemcel-L in the highest-risk adults with steroid-refractory acute graft-versus-host-disease to meet the FDA’s request for additional data.

Findings from a phase 1 trial highlight the potential tolerability and efficacy of ABM-1310 as a treatment for patients with BRAF-mutated solid tumors.

The reduction of hematologic adverse effects with trilaciclib may improve clinical outcomes in patients with extensive-stage small cell lung cancer, according to Jerome Goldschmidt, MD.

Findings from a previous phase 1/2a trial demonstrate that zipalertinib is a potential treatment option for pretreated patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Investigators note that although therapy-related myelodysplastic syndromes or acute myeloid leukemia are not common, efforts to reduce treatment-associated toxicity in survivors of lymphoid neoplasms are needed given the poor prognosis associated with the diagnosis.

Treatment with batiraxcept plus paclitaxel did not produce any new safety signals among patients with platinum-resistant ovarian cancer in the phase 3 AXLerate-OC trial.

Levels of soluble CD163 appear to be higher in those with p53 abnormalities, elevated lactate dehydrogenase, and low hemoglobin in a study cohort of patients with mantle cell lymphoma.

Elraglusib is currently under evaluation as a treatment for patients with several types of advanced cancers as part of the phase 1/2 1801 trial.

The investigational T-cell therapy IVS-3001 is currently under evaluation as part of a phase 1/2 trial in patients with advanced or metastatic solid tumors that are HLA-G positive.

Incorporating PSMA PET into pre-surgical risk assessment may help urologists determine whether surgery should be performed on patients with advanced prostate cancer, according to Loïc Djaïleb, MD, PhD.

Findings from the phase 3 RUBY trial support the FDA’s approval of dostarlimab/chemotherapy as a treatment for advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability–high.

The regulatory agency requests enhanced product testing and additional controls in their market application review of denileukin diftitox for the treatment of those with relapsed/refractory cutaneous T-cell lymphoma.

Investigators of a phase 1 study evaluating cosibelimab in patients with locally advanced or metastatic cutaneous squamous cell carcinoma plan to share updated results at a future medical conference.

Treatment with neoadjuvant pembrolizumab among those with estrogen receptor–positive, HER2-negative breast cancer in the phase 3 KEYNOTE-756 trial does not produce any new safety signals.

Brian Van Tine, MD, PhD, discusses clinical trials assessing several regimens that may lead to novel treatment options for those with desmoid tumors, dedifferentiated liposarcoma, and other hard-to-treat sarcoma subtypes.

The safety profile of trastuzumab deruxtecan among patients with HER2-expressing solid tumors in the phase 2 DESTINY-PanTumor02 trial appears to be comparable with previous reports of the agent.

Investigators will submit data from the phase 3 ENHANCE trial evaluating magrolimab plus azacitidine in higher-risk myelodysplastic syndromes for presentation at a future medical meeting.

Findings from the phase 3 KEYNOTE-811 trial support the CHMP’s recommendation to approve pembrolizumab plus trastuzumab in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Data from the phase 3 QuANTUM-First trial support the FDA’s approval of quizartinib for managing FLT3-ITD–positive acute myeloid leukemia.

The safety profile of pembrolizumab among patients with high-risk locally advanced cervical cancer in the phase 3 KEYNOTE-A18 trial appears to be consistent with previous reports of the agent.

The investigational antibody-drug conjugate ARX517 is currently under evaluation in patients with metastatic castration-resistant prostate cancer as part of the phase 1/2 APEX-01 trial.

Findings from the REBECCA trial support additional research for nurse navigation intervention for managing psychological vulnerability among patients with breast cancer.

Selinexor plus ruxolitinib is under investigation as a treatment for JAK inhibitor-naïve patients with myelofibrosis as part of the phase 3 XPORT-MF-034 trial.